Tate & Lyle: volume growth returned, but EBITDA fell 8%; FY27 outlook held
Tate & Lyle reported volume-led revenue growth, while adjusted EBITDA fell 8% to £197 million on inflation; FY27 guidance unchanged, Ingredion deal pending.
- published on Newsmetry
- original source published
the same feed is available to bots and dashboards through the api. connect the api →
what happened
According to TradingView, Tate & Lyle's revenue grew: one report cites a 1% increase, while the other gives underlying growth of 2% with a 4% contribution from volume and mix. Asia Pacific was a key driver of the result.
Adjusted EBITDA fell 8% to £197 million. The company links the decline to inflation, investment and persistent cost pressure. FY27 guidance was kept unchanged despite inflation and geopolitical uncertainty.
The Ingredion transaction still awaits regulatory clearance. The second report says it remains on track for completion in the second half of 2027.
why it matters
The unchanged FY27 guidance reduces the near-term risk of a downgrade, but inflation pressure on margins remains the central question for investors. The timing of the Ingredion deal is also important for assessing the company.
market impact
Tate & Lyle shares: inflation pressure on margins and Ingredion deal timing are the key investor concerns
tags
instruments
sources
- TATE: Volume-led growth returned, but inflation weighed on earnings; FY27 outlook held — TradingView, 5 November 2026 at 07:09 UTC
- TATE: Volume-led growth returned, but EBITDA declined as cost pressures persisted; FY27 outlook held — TradingView, 5 November 2026 at 08:12 UTC
- TATE: Volume-led growth returned as full-year outlook held amid inflation and uneven demand — TradingView, 5 November 2026 at 09:56 UTC
prepared by the newsmetry newsroom with ai assistance from the sources listed below. not investment advice.
alerts on your topics, the morning digest and the api — in your account.
get stories in real time ↗